DE60303296D1 - Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten - Google Patents

Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten

Info

Publication number
DE60303296D1
DE60303296D1 DE60303296T DE60303296T DE60303296D1 DE 60303296 D1 DE60303296 D1 DE 60303296D1 DE 60303296 T DE60303296 T DE 60303296T DE 60303296 T DE60303296 T DE 60303296T DE 60303296 D1 DE60303296 D1 DE 60303296D1
Authority
DE
Germany
Prior art keywords
ethylphenyl
subject
triazol
methoxyphenyl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60303296T
Other languages
English (en)
Other versions
DE60303296T2 (de
Inventor
L Sigma-Tau Ind Far Battistini
G Sigma-Tau Ind Far Borsellino
Santis R Sigma-Tau Ind Farm De
P Sigma-Tau Ind Farm Carminati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE60303296D1 publication Critical patent/DE60303296D1/de
Publication of DE60303296T2 publication Critical patent/DE60303296T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60303296T 2002-05-03 2003-04-15 Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten Expired - Fee Related DE60303296T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/137,699 US6797722B2 (en) 2002-05-03 2002-05-03 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
US137699 2002-05-03
PCT/IT2003/000237 WO2003092681A1 (en) 2002-05-03 2003-04-15 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-[1,2,4]-triazole for the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
DE60303296D1 true DE60303296D1 (de) 2006-04-06
DE60303296T2 DE60303296T2 (de) 2006-08-17

Family

ID=29269138

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60303296T Expired - Fee Related DE60303296T2 (de) 2002-05-03 2003-04-15 Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten

Country Status (15)

Country Link
US (2) US6797722B2 (de)
EP (1) EP1501505B1 (de)
JP (1) JP2005529904A (de)
KR (1) KR20040111491A (de)
AT (1) ATE315935T1 (de)
AU (1) AU2003224453A1 (de)
CA (1) CA2483904A1 (de)
DE (1) DE60303296T2 (de)
DK (1) DK1501505T3 (de)
ES (1) ES2257666T3 (de)
MX (1) MXPA04010785A (de)
PL (1) PL374252A1 (de)
PT (1) PT1501505E (de)
TW (1) TWI284532B (de)
WO (1) WO2003092681A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
EP1720567A2 (de) * 2004-02-10 2006-11-15 Innate Pharma Zusammensetzung und verfahren zur behandlung von karzinomen
EP1921073A1 (de) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole als Sigma Rezeptoren Hemmstoffe

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379155A (en) * 1979-06-11 1983-04-05 Gruppo Lepetit S.P.A. 3,5-Disubstituted-1H-1,2,4-triazole derivatives
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
DE3808283A1 (de) * 1988-03-12 1989-09-21 Boehringer Ingelheim Kg Neue 3,4,5-substituierte 4h-1,2,4-triazole, ihre herstellung und verwendung
US4895872A (en) * 1989-03-15 1990-01-23 Cetus Corporation Immunosupressive analogues and derivatives of succinylacetone
US5273979A (en) * 1991-08-01 1993-12-28 Merck & Co., Inc. C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
WO1997026278A1 (en) * 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
ATE271028T1 (de) * 1997-04-04 2004-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
IT1292092B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
EP1099695A1 (de) * 1999-11-09 2001-05-16 Laboratoire Theramex S.A. 5-Aryl-1H-1,2,4-triazolverbindungen als Cyclooxygenase-2 Inhibitoren und diese enthaltende pharmazeutische Zusammensetzungen

Also Published As

Publication number Publication date
EP1501505A1 (de) 2005-02-02
WO2003092681A1 (en) 2003-11-13
JP2005529904A (ja) 2005-10-06
TW200418464A (en) 2004-10-01
ES2257666T3 (es) 2006-08-01
EP1501505B1 (de) 2006-01-18
CA2483904A1 (en) 2003-11-13
US20050026980A1 (en) 2005-02-03
PL374252A1 (en) 2005-10-03
DK1501505T3 (da) 2006-05-22
PT1501505E (pt) 2006-05-31
AU2003224453A1 (en) 2003-11-17
ATE315935T1 (de) 2006-02-15
MXPA04010785A (es) 2005-03-07
US20030207931A1 (en) 2003-11-06
KR20040111491A (ko) 2004-12-31
DE60303296T2 (de) 2006-08-17
TWI284532B (en) 2007-08-01
US6797722B2 (en) 2004-09-28

Similar Documents

Publication Publication Date Title
ATE451104T1 (de) Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
EA200500856A1 (ru) Новые химические соединения
BG108857A (en) Glutaminyl based dpiv inhibitors
ATE450268T1 (de) G-csf zur behandlung von amyotropher lateralsklerose
ATE476990T1 (de) Cd20-bindende polypeptidzusammensetzungen
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE60135029D1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE460413T1 (de) Substituierte 1-propinoyl-piperazine mit affinität für den mglur5 rezeptor zur behandlung von schmerzzuständen
DE69936785D1 (de) Zellvermittelte genverabreichung durch verwendung von aus muskeln derivierten zellen zur behandlung der knochen-verwandten verletzung oder störung
DE69329779T2 (de) Verfahren zur behandlung geschädigter oder verminderter zellen
DE602005016729D1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
DE60303296D1 (de) Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE60233555D1 (de) Die nukleotidsequenz ann bindende zink-finger domänen
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
PT672124E (pt) Utilizacao de uma sequencia de dna codificadora de uma proteina que degrada acido oxalico como gene de seleccao
ATE352295T1 (de) Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten
ZA200501629B (en) A method of treatment and prophylaxis
ATE427754T1 (de) Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen
ATE245438T1 (de) Verwendung von oligomerem matrixprotein aus knorpel zur behandlung von rheumatoider arthritis
DE60320848D1 (de) Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen
DE60327925D1 (de) Verwendung von löslichem fgl2 als immunosuppressivum
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee